title: Rioprostil: a clinical experience in gastric ulcer treatment.
abstract: The efficacy and tolerability of the prostaglandin E1 derivative rioprostil (Bay o 6893) was studied in a randomized, double-blind, placebo-controlled trial in 40 patients affected by acute gastric ulcer. At the end of the eight weeks period ulcer healing was achieved in 85% of the rioprostil-treated patients and in 60% of the placebo-treated ones (p less than 0.05). Rioprostil produced a significant reduction of pain and also improved the clinical status. This positive outcome was noted both in smokers and in non-smoking patients, while only this last group improved during the placebo treatment.
authors.affiliation: Division of Medicine, S. Maria della Pietà Hospital, Nola, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Mascio
authors.forename: L
authors.initials: L
authors.lastname: Guida
authors.forename: M V
authors.initials: MV
authors.lastname: Mascio
authors.forename: F
authors.initials: F
authors.lastname: Maggiolo
mesh_terms: D000284:Administration, Oral; D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011458:Prostaglandins E / Q000008:administration & dosage / Q000627:therapeutic use*; D011897:Random Allocation; D016630:Rioprostil; D013276:Stomach Ulcer / Q000188:drug therapy*
chemical_list: D011458:Prostaglandins E; D016630:Rioprostil